PDCD1 and cancer: Although immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-CTLA-4 are becoming standard of care in various cancers, including other forms of liver cancer, few studies have examined the safety and efficacy of ICIs in FLC.